An analysis of the economic impact of drug-coated balloon use for the treatment of peripheral artery disease

• Published in: ICF journal Vol. 3; p. 20
• Main Authors: Micari, Antonio, Vadalà, Giuseppe, Corbo, Mara, D'Alessandro, Gianluigi, Castriota, Fausto, Cremonesi, Alberto
• Format: Journal Article
• Language: English
• Published: 03.09.2015
• ISSN: 2410-2636; 2409-3424
• DOI: 10.17987/icfj.v3i0.115

Background: Drug-coated balloons (DCBs) are an alternative for patients with peripheral arterial disease. Costs and re-intervention rates are potentially reduced compared to other technologies. We assessed the economic impact of these endovascular therapies.Methods: An Italian National Healthcare Service-perspective budget impact model with a 5-year horizon was developed to compare relative costs of 4 index procedures (plain old balloon angioplasty (POBA), DCBs, and bare-metal and drug-eluting stents (BMSs, DESs)) based on 1-year repeat-procedure rates (target-lesion revascularization (TLR)). A published systematic review of TLR rates in patients with femoral-popliteal disease undergoing these treatments was used to measure effectiveness. Costs associated with each treatment were derived from diagnosis-related group tariffs. A decision analytic model was developed to estimate 1-year costs for index procedures and possible revascularizations. Results: Pooled TLR rates show clear patient benefits for DCBs (6.9%) compared with POBA (21.6%) and BMSs (14.2%) and non-inferiority vs. DESs (7.3%). One-year payments for index and repeat interventions (by TLR rate) showed that DCBs were the least costly strategy, saving ~€1,000/patient vs. POBA. The potential savings were €8.7M, assuming 5% annual increase in DCB adoption over 5 years. Conclusions: Despite initial higher investment, DCB represent a cost-saving alternative to other technologies.